PHILADELPHIA - An increased proportion of Indigenous American (IA) ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
"The risk of breast cancer-related mortality varies between different populations, with Latina women having a greater risk of breast cancer-specific mortality than non-Hispanic white women," said Laura Fejerman, PhD, associate professor of medicine at the University of California San Francisco. "Latina women tend to be diagnosed with more aggressive breast cancer subtypes, which may contribute to their greater risk of mortality, among other factors," Fejerman added.
Breast cancers are classified into subtypes based on the status of hormone receptors and the human epidermal growth factor receptor 2 (HER2). These receptors respond to factors outside the cell and promote cellular proliferation. Breast cancers that have higher than normal levels of HER2 are referred to as HER2-positive breast cancers and tend to grow more aggressively than some other subtypes. HER2-positive breast cancers are more common in Latina women than in non-Hispanic white women, but the underlying reasons for this remain unclear.
Previous work from Fejerman and colleagues demonstrated that IA ancestry was associated with a lower incidence of breast cancer. However, the influence of IA ancestry on different breast cancer subtypes remained unclear. A prior study that examined a small cohort of Colombian patients with breast cancer suggested that a higher proportion of IA ancestry was associated with increased expression of the ERBB2 gene, which encodes HER2. This led Fejerman and colleagues to examine whether IA ancestry may be associated with risk of HER2-positive breast cancer.
The Peruvian Genetics and Genomics of Breast Cancer study (PEGEN-BC), led by Fejerman and developed in collaboration with Tatiana Vidaurre, MD, PhD, at the Instituto de Enfermedades Neoplásicas (INEN) in Lima, Peru, recruited 1,842 patients. Participants at INEN were invited to participate in the study if they had received a diagnosis of invasive breast cancer during or after the year 2010 and were between the ages of 21 and 79 years. "Peru is one of the countries in Latin America with extremely high proportions of IA ancestry, which is an understudied genetic component in medical research. The collaboration with Dr. Vidaurre from INEN was fundamental for the realization of this study," Fejerman noted.
The publication reports results from 1,312 patients who had available genome-wide genotype data. HER2-positive breast cancers accounted for 30 percent of cases (18 percent were positive for hormone receptors). On average, participants had approximately 76 percent IA ancestry, with 9.8 percent of patients having greater than 95 percent IA ancestry.
Analyses revealed statistically significant differences in the distribution of different breast cancer subtypes among women with different proportions of IA ancestry. The odds of having a HER2-positive tumor were 1.19 times higher for every 10 percent increase in IA ancestry. Conversely, the odds of developing HER2-positive disease decreased with increasing European ancestry. The observed associations were independent of the participant's age at diagnosis, level of African ancestry, height, tumor stage at diagnosis, and region of residence. The findings were replicated with smaller cohorts from Mexico and Colombia. The odds of having a HER2-positive tumor in these cohorts was approximately 1.28 times greater for every 10 percent increase in IA ancestry.
"The association between IA ancestry and HER2 status suggests that population-specific variants of IA origin could be partly contributing to the higher incidence of HER2-positive breast cancer in Latinas," said Fejerman. "Our ongoing research aims to identify the specific germline variants that may lead to this association." This information could eventually be incorporated into a risk prediction model for Latina women to identify those at high risk for certain subtypes, explained Fejerman. Understanding the genetic basis of the observed association could also help researchers understand the biology of the disease, which could eventually lead to new treatments, Fejerman added.
"Even though humans are mostly the same, there are differences between populations that affect disease risk and outcome," said Fejerman. "This study highlights the importance of studying diverse populations and collaborating with other countries. We need to understand diverse populations so that we may someday be able to provide precision cancer prevention and care to everyone, and not just a subset of the population."
A limitation of the study is that it did not include healthy controls. Additionally, the lack of certain epidemiological data and information about environmental exposures or lifestyle behaviors precluded the analysis of all possible factors.
###
The PEGEN-BC study was supported by the National Institutes of Health/National Cancer Institute and the Instituto Nacional de Enfermedades Neoplásicas. Fejerman declares no conflicts of interest.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 46,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 22,500 attendees. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
Journal
Cancer Research